🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

63 results for “Merck KGaA, Darmstadt, Germany” Clear

  1. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  2. Teriflunomide

    Merck KGaA, Darmstadt, Germany

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  3. V114

    Merck KGaA, Darmstadt, Germany

    Acute Otitis Media (AOM)

    phase 3 mab completed

    1 trial

  4. V114

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  5. V181

    Merck KGaA, Darmstadt, Germany

    Healthy

    phase 3 mab active

    1 trial

  6. Vericiguat

    Merck KGaA, Darmstadt, Germany

    Chronic Heart Failure With Reduced Ejection Fraction

    phase 3 small molecule completed

    1 trial

  7. Zilovertamab vedotin

    Merck KGaA, Darmstadt, Germany

    Diffuse Large B-Cell Lymphoma

    phase 3 mab active

    1 trial

  8. cetuximab + cisplatin + vinorelbine

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule completed

    1 trial

  9. favezelimab/pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Colorectal Cancer

    phase 3 mab completed

    1 trial

  10. pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 3 mab completed

    2 trials

  11. pembrolizumab/vibostolimab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Non-Small-Cell Lung

    phase 3 mab active

    1 trial

  12. Belzutifan

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 2 small molecule active

    1 trial

  13. Cetuximab

    Merck KGaA, Darmstadt, Germany

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  14. DOR/ISL

    Merck KGaA, Darmstadt, Germany

    HIV-1 Infection

    phase 2 small molecule completed

    1 trial

  15. Daptomycin for Injection

    Merck KGaA, Darmstadt, Germany

    Bacteremia

    phase 2 small molecule completed

    1 trial

  16. Docetaxel

    Merck KGaA, Darmstadt, Germany

    Castration-Resistant Prostatic Cancer

    phase 2 small molecule active

    1 trial

  17. Doravirine

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    phase 2 small molecule active

    1 trial

  18. Efinopegdutide

    Merck KGaA, Darmstadt, Germany

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  19. Efinopegdutide 20 mg/mL

    Merck KGaA, Darmstadt, Germany

    Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  20. Intismeran autogene

    Merck KGaA, Darmstadt, Germany

    Malignant Melanoma

    phase 2 mab active

    1 trial

  21. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  22. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  23. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  24. MK-6194

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources